Introduction {#Sec1}
============

Cancer became a major reason of death \[[@CR1]\]. More than four millions new cancer cases reported in developed countries \[[@CR2], [@CR3]\]. Molecular targeting strategies were used to treat distributed cancer depending on identifying the tumor suppressors and oncogenes involved in the progress of human cancers \[[@CR4]\]. Tyrosine kinase inhibitors (TKIs) (e.g. masitinib) are compounds that target tyrosine kinases enzymes, which are responsible for the activation of numerous proteins in a number of cell signaling pathways. They initiate or stop many functions inside living cells \[[@CR5]\]. Blocking the selected activation of these proteins has been shown to have therapeutic benefits in cancer diseases and central nervous system disorders mast cells and macrophages \[[@CR6], [@CR7]\]. Tyrosine kinase inhibitors (TKIs) are considered a very important class of targeted therapy \[[@CR8]\].

MST (Fig. [1](#Fig1){ref-type="fig"}) is new orally administered TKIs. It is already registered in Europe and USA for the treatment of mast cell tumors in dogs \[[@CR9]\]. MST is approved under the trade name masivet in Europe and Kinavet in the USA at a dose of 12.5 mg kg^−1^ per day \[[@CR10]\]. Toxicity profile of MST is lower than other TKIs \[[@CR11]\]. MST selectively inhibits c-kit tyrosine kinase blocking stem cell factor induced proliferation. It exhibits more activity and selectivity against KIT than imatinib in in vitro studies \[[@CR11]\]. In 3 October 2016, AB Science announced that the EMA has accepted a conditional marketing authorization application for MST to treat ALS in human. MST found to be effective for the treatment of severely symptomatic indolent or smouldering systemic mastocytosis \[[@CR12]\].Fig. 1Chemical structure of MST

Drug metabolism research is an integral part of the drug discovery process and is very often the factor that determines the success of a given drug to be marketed and clinically used \[[@CR13]\]. Drug metabolism research is generally conducted using in vitro and/or in vivo techniques. In vitro techniques involve the incubation of drugs with different types of in vitro preparations (e.g. liver microsomes, hepatocytes) isolated from rats and subsequent sample processing and analysis using spectroscopic techniques \[[@CR14], [@CR15]\]. In vivo techniques involve the administration of a single dose of the drug to rat, and the subsequent collection of urine that contain the drugs and their potential metabolites. In this work, we focused in the in vivo phase I metabolites and in vivo phase II MST metabolites identification using LC--MS/MS \[[@CR16]\]. All measurements were done using Agilent LC--MS/MS system that consisted of LC (Agilent HPLC 1200) coupled to MS/MS detector (6410 QqQ MS) through an electrospray ionization source (Agilent Technologies, USA) \[[@CR17]\].

MST chemical structure contains cyclic tertiary amine. Phase I metabolism of cyclic tertiary amines produces metabolites of oxidative products including N-dealkylation, ring hydroxylation, α-carbonyl formation, N-oxygenation, and ring opening metabolites that can be formed through iminium ion intermediates \[[@CR18], [@CR19]\].

Chemicals and methods {#Sec2}
=====================

Chemicals {#Sec3}
---------

All chemicals are listed in Table [1](#Tab1){ref-type="table"}.Table 1List of materials and chemicalsName^a^SourceMasitinibLC Labs (USA)Tween 80Eurostar Scientific Ltd. (UK)Ammonium formate, HPLC grade acetonitrile (ACN), Dimethyl Sulfoxide (DMSO), Polyethylene glycol 300 (PEG 300) and formic acidSigma-Aldrich (USA).Water (HPLC grade)Milli-Q plus purification system (USA)Sprague--Dawley ratsAnimal Care Center, College of Pharmacy, King Saud University (Saudi Arabia)^a^ All solvent are HPLC grade and reference powders are of AR grade

In vivo metabolism of MST in Sprague--Dawley Rats {#Sec4}
-------------------------------------------------

### Rat dosing protocol {#Sec5}

Male Sprague--Dawley rats (n = 6, average: 340 g, 4 weeks of age) were housed individually in special purpose metabolism cages. Cages are placed in the animal care facility in a 12 h light/dark cycle (7:00--19:00) and were allowed free access to standard animal feed and water that were placed in the special food and water compartments attached to the metabolism cages. Rats were acclimated in metabolism cages for 72 h prior to the start of the study. MST was formulated in (4% DMSO, 30% PEG 300, 5% Tween 80, HPLC H~2~O) for oral dosing of rats. Doses were individually calculated for each rat such that everyone receives a specific dose. The average dose of MST (Kinavet-CA1) in dogs was 10 mg kg^−1^. By using the following equations \[[@CR20]--[@CR22]\]:$$\documentclass[12pt]{minimal}
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So the dose for each rat was 33.3 mg/kg. All rats except one were given a single dose of MST. All MST doses were administered by oral gavage. Urine draining into the special urine compartments fitted to the metabolism cages were collected prior to drug dosing as blank control reference and at 6, 12, 18, 24, 48, 72 and 96 h following MST dosing. Urine samples taken from all metabolism cages were pooled together, labeled, and stored at (− 20 °C).

### Sample preparation {#Sec6}

Urine samples were thawed to room temperature and filtered over 0.45 µm syringe filters. Liquid liquid extraction (LLC) was used to extract MST and its related metabolites. Equal volume of ice cold acetonitrile (ACN) was added to each sample then vigorously shaken by vortexing for 1 min. Phase separation \[[@CR23], [@CR24]\] between an aqueous sample and a water-miscible solvent (ACN) into two layers achieved by using ice cold ACN that was added to urine and the mixture was stored at 4 °C overnight \[[@CR25]\]. Low temperature leads to phase separation of ACN/urine mixture. The *p*H of urine and the nature of urine matrix which contains high concentration of salt participated in phase separation \[[@CR26]\]. As we did not want to miss any MST-related metabolites, both layers were removed and evaporated to dryness under stream of nitrogen. The dried extracts were reconstituted in 1 mL of mobile phase and transferred to 1.5 mL HPLC vials for LC--MS/MS analysis. Control urine samples obtained from rats prior to drug dosing were prepared in the exact way described for each method of sample purification.

LC--MS/MS conditions {#Sec7}
--------------------

The LC--MS/MS parameters optimized for chromatographic separation and identification of rat urine extract components are listed in Table [2](#Tab2){ref-type="table"}.Table 2Adjusted parameters of the supposed LC--MS/MS methodologyParameters of LCParameters of MS/MSHPLCAgilent 1200Mass spectrometerAgilent 6410 QQQGradient mobile phaseA: H~2~O (10 mM Ammonium formate,\
pH:4.1)Ionization sourcePositive ESIB: ACNDrying gas: N~2~ gas\
Flow rate (12 L/min)\
Pressure (55 psi)Flow rate: 0.2 mL/minRun time: 45 minInjection volume: 20 µLAgilent eclipse plus C~18~ columnLength50 mmESI temperature: 350 °CInternal diameter2.1 mmCapillary voltage: 4000 VParticle size1.8 μmCollision gasHigh purity N~2~Temperature:24 °CModesMass scan and product ion (PI)Gradient systemTime%BAnalyteMST and its related in vivo phase I and phase II metabolites054040Mass parametersFragmentor voltage: 130 V4340455Post time (15 min)5Collision energy of 20 eV

Identification of in vivo MST metabolites {#Sec8}
-----------------------------------------

MST-related metabolites were concentrated in the ACN layer while endogenous urine components and polar metabolites (e.g. glucuronide conjugates) were found in the aqueous layer. Extracted ion chromatograms for the expected metabolites were used to find metabolites in the total ion chromatogram of both organic and aqueous layers. PI studies were for the suspected compounds and results were interpreted and compared with the PI of MST. Mass scan and PI scan modes of the triple quadrupole mass analyzer were used for detection of in vivo phase I and phase II MST metabolites. PI mass spectra were used to propose the metabolite chemical structure by reconstructing the marker daughter ions.

Results and discussion {#Sec9}
======================

Identification of in vivo phase I metabolic pathways of MST {#Sec10}
-----------------------------------------------------------

The in vivo metabolites of MST underwent fragmentations similar to that of the parent ion that allowed us to identify and determine changes in the metabolite structures. The product ion mass spectra of some metabolites exhibited particular fragmentation pathways that provided more structural information as shown below. Comparison of PI mass spectra between urine extracts with control samples in addition to the comparison of PI of MST and its anticipated metabolites (Table [3](#Tab3){ref-type="table"}) resulted in the detection of twenty in vivo phase I and four phase II metabolites (Fig. [2](#Fig2){ref-type="fig"}). Ten in vivo phase I metabolites are reported in the case of in vitro metabolism \[[@CR27]\]. We concentrated on the structural identification of the new ten in vivo phase I and the other four in vivo phase II MST metabolites. Metabolic pathways for in vivo phase I metabolites were supposed to be N-demethylation, N-oxide formation, oxidation, oxidative deamination, reduction, oxidative cleavage, benzyl oxidation and hydroxylation while for phase II metabolites were N-conjugation of MST and the N-demethyl metabolite with glucuronic acid and oxidative metabolites glucuronidation.Table 3*In vivo* phase I MST metabolites\[M + H\]^+^PIRT (min)In vivo phase I metabolic reactionMST49939924.9M148539927.9N-demethylationM250140126.6Carbonyl group reductionM3501400.2, 367.324.4N-demethylation and Hydroxylation of pyridine ringM4501482.9, 399.326.5N-demethylation and Hydroxylation of N-methyl piperazineM5529511, 42925.1Benzyl oxidation to carboxylic acidM6529486, 40026.9Pyridine ring hydroxylation and N-methyl piperazine oxidationM7529511,482 399, 24729.6Oxidation and Hydroxylation of N-methyl piperazineMO1515497.2, 415, 396.821.7N-oxide formationMO2515497.2, 396.922.2Benzylic hydroxylationMO3515497.0, 400.123.0Pyridine ring hydroxylationMO4515497, 399, 415, 21723.1Pyridine ring N-oxidationMO5515497, 399, 415, 21724.0N-oxidationMO6515428, 415, 400, 381.3, 98.1,28.0Piperazine ring N-oxidationM8531488, 402, 12326.7Pyridine ring hydroxylation and piperazine ring hydroxylationM9531415, 381, 12327.3Piperazine ring hydroxylation and benzyl hydroxylationM10531501, 40129.3Oxidative cleavage of N-methyl piperazine ring to carboxylic acidM1154751130.7N-oxide formation of pyridine and piperazine ring and Benzylic hydroxylation \[[@CR27]\]MA143125510.2Oxidative deaminationMA244727113.2Phenyl hydroxylation and oxidative deaminationMA3447285, 271, 164, 11114.5Benzyl hydroxylation and oxidative deamination Fig. 2PI chromatograms: **a** (MST), **b** (M1), **c** (M2--M4), **d** (M5--M7), **e** (M8--M10) and **f** (MO1--MO6)

### MST excretion of in rat urine {#Sec11}

Part of the MST oral dose was excreted unmetabolized in rat urine. MST parent ion was detected at *m/z* 499 in full mass scan spectrum. MST of and its major in vivo metabolites (M1 and MO6) excretion in urine was observed after 6 h of dosing. Comparative concentrations of MST, M1 and MO6 were high after 6 h and then began to decline by time until almost vanished after 96 h from dosing as shown in the overlayed PI chromatograms (Check Additional file [1](#MOESM1){ref-type="media"}). Peak area ratios of MST and its major metabolite (M1 and MO6) in urine were plotted against time. Peak area ratio of each MST, M1 and MO6 were measured at different collection time considering the biggest peak is 100% (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR28]\].Fig. 3MST, M1 and MO6 excretion rate

Fragmentation of MST (Fig. [4](#Fig4){ref-type="fig"}) was explained in Scheme [1](#Sch1){ref-type="fig"}. Comparison of PI of MST with suspected peaks allowed the identification of metabolic changes in the supposed in vivo metabolites.Fig. 4PI of MST parent ion at *m/z* 499 Scheme 1Supposed PI of MST

### M1 in vivo phase I metabolite {#Sec12}

The major metabolic pathway for MST is N-demethyalation. M1 was detected at *m/z* 485 in mass scan spectrum.

### M2, M3 and M4 in vivo phase I metabolite {#Sec13}

M2, M3 and M4 were detected at *m/z* 501 at different retention times in mass scan spectrum of organic urine extract. PI scan for the three metabolites gave different daughter ions. In the case of M2, parent ion at *m/z* 501 was fragmented to one ion at *m/z* 401. The daughter ion at *m/z* 401 supposed that there is no change in the methyl piperazine group. The metabolic pathway for M2 metabolite was supposed to be the reduction of the carbonyl group.

In the case of M3, parent ion at *m/z* 501 was fragmented to ions at 400.2 and 367.2 (Fig. [5](#Fig5){ref-type="fig"}). Metabolic pathways for M3 were supposed to be hydroxylation of pyridine ring and N-demethylation (Scheme [2](#Sch2){ref-type="fig"}).Fig. 5PI mass spectrum of parent ion (M3) at *m/z* 502 Scheme 2Supposed PIs of M3

In the case of M4, parent ion at *m/z* 501 was fragmented to two daughter ions at *m/z* 483 and at *m/z* 399 (Fig. [6](#Fig6){ref-type="fig"}). The daughter ion at *m/z* 399 supposed that there all metabolic changes occured in the methyl piperazine group. Metabolic pathways for M4 metabolite were hydroxylation and N-demethylation of N-methyl piperazine (Scheme [3](#Sch3){ref-type="fig"}).Fig. 6PI mass spectrum of parent ion (M4) at *m/z* 501 Scheme 3Supposed PIs of M4

### MO1 to MO6 in vivo phase I metabolite {#Sec14}

Oxidized MST metabolite (M + O) was detected at *m/z* 515 in mass scan spectrum at different retention times. Fragmentation of parent ions at *m/z* 515 gave different daughter ions as shown in the Table [3](#Tab3){ref-type="table"}. The structure of each metabolite was supposed The metabolic pathway for MO metabolites was supposed to be either by hydroxylation or N-oxidation of MST \[[@CR27]\].

### M5, M6 and M7 in vivo phase I metabolite {#Sec15}

M5, M6 and M7 metabolites were detected at *m/z* 529 in full mass scan spectrum at different retention times. PI scan for parent ions at *m/z* 529 gave different daughter ions. In the case of M5, parent ion at *m/z* 529 was fragmented to ions at *m/z* 511 and at *m/z* 429 (Fig. [7](#Fig7){ref-type="fig"}). The metabolic pathway for M5 was supposed to be benzyl oxidation to carboxylic acid (Scheme [4](#Sch4){ref-type="fig"}).Fig. 7PI mass spectrum of parent ion (M5) at *m/z* 529 Scheme 4Supposed PIs of M5

In the case of M6, parent ion at *m/z* 529 was fragmented to ions at 486 and 400 (Fig. [8](#Fig8){ref-type="fig"}). The metabolic pathway for M6 was supposed to be hydroxylation and oxidation of methyl piperazine ring (Scheme [5](#Sch5){ref-type="fig"}).Fig. 8PI mass spectrum of parent ion (M6) at *m/z* 529 Scheme 5Supposed PIs of M6

In the case of M7, parent ion at *m/z* 529 was fragmented to ions at 511, 399 and 98 (Fig. [9](#Fig9){ref-type="fig"}). Metabolic pathways for M7 were supposed to be hydroxylation and oxidation of methyl piperazine ring (Scheme [6](#Sch6){ref-type="fig"}).Fig. 9PI mass spectrum of parent ion (M7) at *m/z* 529 Scheme 6Supposed PIs of M7

### M8, M9 and M10 in vivo phase I metabolite {#Sec16}

M8, M9 and M10 metabolites were detected at *m/z* 531 in full mass scan spectrum at different retention times. PI scan for parent ions at *m/z* 531 gave different daughter ions. In the case of M8, parent ion at *m/z* 531 was fragmented to ions at 488, 402 and 123 (Fig. [10](#Fig10){ref-type="fig"}). Metabolic pathways for M8 were supposed to be hydroxylation of pyridine and hydroxylation of methyl piperazine ring (Scheme [7](#Sch7){ref-type="fig"}).Fig. 10PI mass spectrum of parent ion (M8) at *m/z* 531 Scheme 7Supposed PIs of M8

In the case of M9, parent ion at *m/z* 531 was fragmented to ions at 513, 415, 381 and 123 (Fig. [11](#Fig11){ref-type="fig"}). Metabolic pathways for M9 were supposed to be benzyl hydroxylation and hydroxylation of methyl piperazine ring (Scheme [8](#Sch8){ref-type="fig"}).Fig. 11PI mass spectrum of parent ion (M9) at *m/z* 531 Scheme 8Supposed PIs of M9

In the case of M10, parent ion at *m/z* 531 was fragmented to ions at 501 and 401 (Fig. [12](#Fig12){ref-type="fig"}). Metabolic pathways for M10 were supposed to be oxidative cleavage of N-methyl piperazine ring to carboxylic acid (Scheme [9](#Sch9){ref-type="fig"}).Fig. 12PI mass spectrum of parent ion (M10) at *m/z* 531 Scheme 9Supposed PIs of M10

### M11 in vivo phase I metabolite {#Sec17}

M11 was detected at *m/z* 547 in mass scan spectrum of the urine organic extract. PI chromatogram of urine organic extract at *m/z* 547 showed one peak at 30.72 min. PI scan for M11 at *m/z* 547 gave daughter ions at *m/z* 511. Metabolic reactions for M11 metabolite were supposed to be hydroxylation of benzylic carbon, oxidation of pyridine nitrogen and oxidation of piperazine nitrogen.

### In vivo phase I oxidative deamination metabolic pathway (MA1, MA2 and MA3) {#Sec18}

The loss of the piperazine moiety by oxidative deamination and rapid further oxidation of the intermediate aldehyde to a carboxylic acid metabolite were observed for MA1, MA2 and MA3 in the aqueous layer of the urine/ACN mixture. Fragmentation of parent ions at *m/z* 431 and at *m/z* 447 gave different daughter ions. The structure of each metabolite was supposed.

MA1 was detected at *m/z* 431 in mass scan spectrum of the aqueous layer urine extract. PI chromatogram of urine aqueous extract at *m/z* 431 showed one peak at 10.2 min. PI scan for MA1 at *m/z* 431 gave daughter ions at *m/z* 255 (Fig. [13](#Fig13){ref-type="fig"}). The daughter ion at *m/z* 255 supposed the loss of the piperazine moiety by oxidative deamination and rapid further oxidation of the intermediate aldehyde to a carboxylic acid (Scheme [10](#Sch10){ref-type="fig"}).Fig. 13PI mass spectrum of parent ion (MA1) at *m/z* 431 Scheme 10Supposed PIs of MA1

MA2 and MA3 were detected at *m/z* 447 in mass scan spectrum of the aqueous layer urine extract. PI chromatogram of urine aqueous extract at *m/z* 447 showed two peaks at 18.6 and 19.5 min. PI scan for MA2 and MA3 at *m/z* 447 gave different daughter ions at two different retention times (Figs. [14](#Fig14){ref-type="fig"} and [15](#Fig15){ref-type="fig"}).Fig. 14PI mass spectrum of parent ion (MA2) at *m/z* 447 Fig. 15PI mass spectrum of parent ion (MA3) at *m/z* 447

In the case of MA2, the daughter ion at *m/z* 271 supposed the loss of the piperazine moiety by oxidative deamination and rapid further oxidation of the intermediate aldehyde to a carboxylic acid in addition to phenyl hydroxylation (Scheme [11](#Sch11){ref-type="fig"}).Scheme 11Supposed PIs of MA2

In the case of MA3, the daughter ion at *m/z* 271 supposed the loss of the piperazine moiety by oxidative deamination and rapid further oxidation of the intermediate aldehyde to a carboxylic acid. The other daughter ion at *m/z* 285 supposed benzyl hydroxylation (Scheme [12](#Sch12){ref-type="fig"}).Scheme 12Supposed PIs of MA3

Identification of in vivo phase II metabolic pathways of MST {#Sec19}
------------------------------------------------------------

Phase II metabolic pathways were supposed to be N-conjugation of MST and the N-demethyl metabolite with glucuronic acid, and glucuronidation of oxidative metabolites (Table [4](#Tab4){ref-type="table"}). Phase II metabolites were found in the aqueous layer of the rat urine extract in a very small concentration compared to in vivo phase I metabolites. Excretion of all in vivo phase II metabolites in urine was observed after 12 h of rat dosing and disappeared rapidly after 48 h of rat dosing.Table 4In vivo phase II MST metabolitesMass scanDaughter ionsRetention time (min)Phase II metabolic pathwayMG1675499, 39918.93Direct N-conjugation with glucuronic acidMG266148518.77N-demethylation and direct N-conjugation with glucuronic acidMG3691514.818.7Glucuronidation of hydroxy MST at N-methyl piperazine ringMG4691515.3, 414.919.46Glucuronidation of hydroxy MST at benzyl carbon

### MG1 in vivo phase II metabolite {#Sec20}

MG1 was detected at *m/z* 675 in mass scan spectrum of the aqueous layer urine extract. PI chromatogram of urine aqueous extract at *m/z* 675 showed one peak at 18.9 min. PI scan for MG1 at *m/z* 675 gave daughter ions at *m/z* 499 and 399 (Fig. [16](#Fig16){ref-type="fig"}). The daughter ion at *m/z* 399 supposed that direct N-conjugation of MST with glucuronic. The other daughter ion at 499 refers to the aglycone (MST) formed in the triple quadrupole by the loss of anhydroglucuronic acid (Scheme [13](#Sch13){ref-type="fig"}).Fig. 16PI mass spectrum of parent ion (MG1) at *m/z* 675 Scheme 13Supposed PIs of MG1

### MG2 in vivo phase II metabolite {#Sec21}

MG2 was detected at *m/z* 661 in mass scan spectrum of the aqueous layer urine extract. PI chromatogram of urine aqueous extract at *m/z* 661 showed one peak at 18.7 min. PI scan for MG2 at *m/z* 661 gave daughter ions at *m/z* 485 (Fig. [17](#Fig17){ref-type="fig"}). The daughter ion at 485 refers to the aglycone (N-demethyl MST) formed in the triple quadrupole by the loss of anhydroglucuronic acid (Scheme [14](#Sch14){ref-type="fig"}).Fig. 17PI mass spectrum of parent ion (MG2) at *m/z* 661 Scheme 14Supposed PIs of MG2

### MG3 and MG4 in vivo Phase II metabolites {#Sec22}

MG3 and MG4 were detected at *m/z* 691 in mass scan spectrum of the aqueous layer urine extract. PI chromatogram of urine aqueous extract at *m/z* 691 showed two peaks at 18.6 and 19.5 min. PI scan for MG3 and MG4 at *m/z* 691 gave different daughter ions at two different retention times (Figs. [18](#Fig18){ref-type="fig"}, [19](#Fig19){ref-type="fig"}).Fig. 18PI mass spectrum of parent ion (MG3) at *m/z* 691 Fig. 19PI mass spectrum of parent ion (MG4) at *m/z* 691

In the case of MG3, the daughter ion at *m/z* 515 supposed that direct O-glucuronidation of hydroxy MST. The daughter ion at 515 refers to the aglycone (hydroxy MST) formed in the triple quadrupole by the loss of anhydroglucuronic acid. (Scheme [15](#Sch15){ref-type="fig"}). Hydroxylation was supposed to be in the N-methyl piperazine ring. In the case of MG4, the daughter ion at *m/z* 515 supposed that direct O-glucuronidation of hydroxy MST. The daughter ion at 515 refers to the aglycone (hydroxy MST) formed in the triple quadrupole by the loss of anhydroglucuronic acid (Scheme [16](#Sch16){ref-type="fig"}). The other daughter at *m/z* 415 supposed that the hydroxylation of benzyl carbon.Scheme 15Supposed PIs of MG3 Scheme 16Supposed PIs of MG4

Conclusions {#Sec23}
===========

MST was excreted partially unchanged in rat urine. Twenty in vivo phase I metabolites were formed by oral dosing of MST to Sprague--Dawley rats through six metabolic pathways: N-demethylation, N-oxidation, oxidation, reduction, hydroxylation and oxidative deamination. Four in vivo phase II glucuronide conjugates were found in the aqueous layer of rat urine extract (Fig. [20](#Fig20){ref-type="fig"}).Fig. 20Chemical structure of MST and identified metabolic pathways in Rat. The main metabolic pathway was the N-demethylation
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